Evidence map›Paper›PMID 39711116›Full record

ArticleJournal of medicinal chemistry2025

Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.

Alex G Baldwin, David W Foley, Ross Collins, Hyunah Lee, D Heulyn Jones, Ben Wahab, Loren Waters, Josephine Pedder, Marie Paine, Gui Jie Feng and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Alex G BaldwinMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.ORCID 0000-0002-7126-5220
David W FoleyMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Ross CollinsMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Hyunah LeeCentre for Medicines Discovery, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, U.K.
D Heulyn JonesMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Ben WahabMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Loren WatersMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Josephine PedderMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Marie PaineMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Gui Jie FengMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.ORCID 0000-0002-6145-8504
Lucia PriviteraDivision of Neuroscience, School of Medicine, Medical Sciences Institute, Dundee University, Dow Street, Dundee DD1 5HL, U.K.
Alexander Ashall-KellyMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Carys ThomasMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Jason A GillespieMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Lauramariú SchinoMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Delia BelelliDivision of Neuroscience, School of Medicine, Medical Sciences Institute, Dundee University, Dow Street, Dundee DD1 5HL, U.K.
Cecilia RochaThe Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
Gilles MaussionThe Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
Andrea I KrahnThe Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
Thomas M DurcanThe Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
Jonathan M ElkinsCentre for Medicines Discovery, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, U.K.ORCID 0000-0003-2858-8929
Jeremy J LambertDivision of Neuroscience, School of Medicine, Medical Sciences Institute, Dundee University, Dow Street, Dundee DD1 5HL, U.K.
John R AtackMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.
Simon E WardMedicines Discovery Institute, School of Biosciences, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, U.K.ORCID 0000-0002-8745-8377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LIMKs are serine/threonine and tyrosine kinases responsible for controlling cytoskeletal dynamics as key regulators of actin stability, ensuring synaptic health through normal synaptic bouton structure and function. However, LIMK1 overactivation results in abnormal dendritic synaptic development that characterizes the pathogenesis of Fragile X Syndrome (FXS). As a result, the development of LIMK inhibitors represents an emerging disease-modifying therapeutic approach for FXS. We report the discovery of MDI-114215 (

Indexed as

Fragile X SyndromeLim KinasesProtein Kinase InhibitorsActin Depolymerizing FactorsAnimalsDrug DiscoveryHippocampusHumansInduced Pluripotent Stem CellsLong-Term PotentiationMaleMiceMice, Inbred C57BLNeuronsStructure-Activity RelationshipActin Depolymerizing FactorsLIMK1 protein, humanLIMK2 protein, humanLim KinasesProtein Kinase Inhibitors

Identifiers

PMID39711116
PMCPMC11726654

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.